Additionally, the 36-month beta value for ONTX is 1.35. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ONTX is 20.84M and currently, short sellers hold a 0.10% ratio of that float. The average trading volume of ONTX on April 02, 2024 was 77.62K shares.
ONTX) stock’s latest price update
Onconova Therapeutics Inc (NASDAQ: ONTX)’s stock price has decreased by -19.69 compared to its previous closing price of 1.00. However, the company has seen a -8.73% decrease in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-28 that NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D.
ONTX’s Market Performance
Onconova Therapeutics Inc (ONTX) has experienced a -8.73% fall in stock performance for the past week, with a -3.23% drop in the past month, and a 7.71% rise in the past quarter. The volatility ratio for the week is 6.97%, and the volatility levels for the past 30 days are at 8.27% for ONTX. The simple moving average for the past 20 days is -11.45% for ONTX’s stock, with a -0.82% simple moving average for the past 200 days.
Analysts’ Opinion of ONTX
Many brokerage firms have already submitted their reports for ONTX stocks, with Ladenburg Thalmann repeating the rating for ONTX by listing it as a “Buy.” The predicted price for ONTX in the upcoming period, according to Ladenburg Thalmann is $7 based on the research report published on March 01, 2022 of the previous year 2022.
Guggenheim, on the other hand, stated in their research note that they expect to see ONTX reach a price target of $4. The rating they have provided for ONTX stocks is “Buy” according to the report published on May 18th, 2021.
H.C. Wainwright gave a rating of “Buy” to ONTX, setting the target price at $7.50 in the report published on March 01st of the previous year.
ONTX Trading at 2.04% from the 50-Day Moving Average
After a stumble in the market that brought ONTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.61% of loss for the given period.
Volatility was left at 8.27%, however, over the last 30 days, the volatility rate increased by 6.97%, as shares sank -4.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.90% upper at present.
During the last 5 trading sessions, ONTX rose by +1.16%, which changed the moving average for the period of 200-days by -23.27% in comparison to the 20-day moving average, which settled at $0.9049. In addition, Onconova Therapeutics Inc saw 7.71% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ONTX
Current profitability levels for the company are sitting at:
- -95.44 for the present operating margin
- 0.93 for the gross margin
The net margin for Onconova Therapeutics Inc stands at -85.85. The total capital return value is set at -1.24. Equity return is now at value -97.22, with -61.07 for asset returns.
Currently, EBITDA for the company is -20.3 trillion with net debt to EBITDA at 1.17. When we switch over and look at the enterprise to sales, we see a ratio of -32.57. The receivables turnover for the company is 12.56for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.46.
Conclusion
In conclusion, Onconova Therapeutics Inc (ONTX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
